Type Whole antibody Target TGF beta 2 CAS Number 285985-06-0 | Source Human ATC code none | |
Legal status Development discontinued | ||
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results.
References
Lerdelimumab Wikipedia(Text) CC BY-SA